Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy

NCT00549692 is registered in ClinicalTrials.gov with Kuhnil Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00549692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00549692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy
Lead sponsor
Kuhnil Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2007
Completion date
September 30, 2012
Enrollment
152 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy